Table 1.
Characteristics of included studies
| Study | Number participants | Type of study | Laboratory parameter | Severe disease |
Non-Severe disease |
||
|---|---|---|---|---|---|---|---|
| n (%) | Age (years) | n (%) | Age (years) | ||||
| Almazeedi et al. [19] | 1096 | Retrospective cohort | Procalcitonin, Albumin, CRP, D-Dimer | 42 (3.8%) | 54.8 ± 11 | 1054 (96.2%) | 37.1 ± 16 |
| Alshukry et al. [20] | 193 | Retrospective cohort | Procalcitonin, Albumin, CRP, D-Dimer, LDH | 22 (11.4%) | 52.3 ± 13.5 | 171 (88.6%) | 44.6 ± 15.7 |
| Cheng et al. [21] | 456 | Retrospective cohort | Procalcitonin, Albumin, CRP, D-Dimer, LDH | 251 (55%) | 59.8 ± 17.4 | 205 (45%) | 48.9 ± 18.1 |
| Dreher et al. [22] | 50 | Prospective cohort | Procalcitonin, CRP, D-Dimer, LDH | 24 (48%) | 63.3 ± 8.8 | 26 (52%) | 69.3 ± 16.2 |
| Duan et al. [23] | 348 | Retrospective cohort | Procalcitonin, Albumin, CRP, D-Dimer | 20 (5.7%) | 58 ± 15 | 328 (94.3%) | 44 ± 15 |
| Feng et al. [24] | 406 | Retrospective cohort | Procalcitonin, Albumin, CRP, D-Dimer, LDH | 54 (13.3%) | 57.6 ± 14 | 352 (86.7%) | 50.3 ± 19.2 |
| Gao et al. [25] | 43 | Retrospective cohort | Procalcitonin, CRP, D-Dimer | 15 (34.8%) | 45.2 ± 7.6 | 28 (65.2%) | 42.9 ± 14 |
| Gong et al. [26] | 189 | Retrospective cohort | Procalcitonin, CRP, Albumin, D-Dimer, LDH | 28 (14.8%) | 63.3 ± 12.9 | 161 (86.2%) | 46.6 ± 21.4 |
| Huang et al. [27] | 41 | Prospective cohort | Procalcitonin, Albumin, D-Dimer, LDH | 13 (31.7%) | 50.3 ± 14.8 | 28 (68.3%) | 49.1 ± 12.2 |
| Jiang et al. [28] | 60 | Retrospective cohort | D-Dimer | 8 (13.3%) | 56.3 ± 27.4 | 52 (86.7%) | 40.3 ± 42.2 |
| Khamis et al. [29] | 63 | Retrospective cohort | CRP, D-Dimer, LDH | 24 (38%) | 50 ± 17 | 39 (62%) | 47 ± 16 |
| Lv et al. [30] | 270 | Retrospective cohort | Procalcitonin, CRP, D-Dimer | 155 (57.4%) | 58.6 ± 47.4 | 115 (42.6%) | 54.3 ± 41.4 |
| Shang et al. [31] | 443 | Retrospective cohort | Procalctionin, Albumin, CRP, D-Dimer, LDH | 139 (31.3%) | 63.6 ± 14 | 304 (68.7%) | 57.3 (14.8) |
| Shi et al. [32] | 134 | Retrospective cohort | Procalcitonin, Albumin, CRP, D-Dimer, LDH | 46 (34.3%) | 56 ± 14.8 | 88 (65.7%) | 40 ± 15.5 |
| Sun et al. [33] | 18 | Prospective cohort | Albumin, CRP, D-Dimer, LDH | 10 (55.5%) | 59 ± 38.5 | 8 (44.5%) | 24.6 ± 33.3 |
| Wan et al. [34] | 135 | Retrospective case series | Procalcitonin, Albumin, CRP, D-Dimer, LDH | 40 (29.6%) | 60.3 ± 15.5 | 95 (70.4%) | 42 ± 11.8 |
| Wang et al. [35] | 45 | Retrospective cohort | Albumin, D-Dimer, LDH | 10 (22.2%) | 44.3 ± 25.1 | 35 (77.8%) | 38.6 ± 34 |
| Wang et al. [36] | 138 | Retrospective cohort | Procalcitonin, D-Dimer, LDH | 36 (26%) | 67 ± 15.5 | 102 (74%) | 50 ± 18.5 |
| Wei et al. [37] | 167 | Retrospective cohort | Procalcitonin, Albumin, CRP, D-Dimer, LDH | 30 (17.9%) | 49 ± 12.6 | 137 (82.1%) | 40.8 ± 15.4 |
| Yang et al. [38] | 200 | Retrospective cohort | Procalcitonin, Albumin, CRP, D-Dimer, LDH | 29 (14.5%) | 71 ± 13.4 | 171 (85.5%) | 52 ± 16.2 |
| Yi et al. [39] | 100 | Retrospective cohort | Procalcitonin, CRP, D-Dimer | 49 (49%) | 60.6 ± 14 | 51 (51%) | 48 ± 16.2 |
| Zhang et al. [40] | 140 | Retrospective cohort | Procalcitonin, CRP, D-Dimer | 56 (40.5%) | 58.6 ± 45.9 | 82 (59.5%) | 51.8 ± 38.5 |
| Zhang et al. [41] | 113 | Retrospective cohort | Procalcitonin, Albumin, CRP, LDH | 61 (53.9%) | 53.6 ± 13.3 | 52 (46.1%) | 34.2 ± 19.6 |